
Expanding Broader Patient Access to CGTs
At Asembia’s ASX25 Summit, a session on cell and gene therapies (CGTs) explored how the field is rapidly evolving amid a shift toward allogeneic therapies and expanded treatment sites, with a robust pipeline with 50 products and a projected $80 billion …